|
[1]
|
Lane, C.A., Hardy, J. and Schott, J.M. (2018) Alzheimer’s Disease. European Journal of Neurology, 25, 59-70.
https://doi.org/10.1111/ene.13439
|
|
[2]
|
Cummings, J.L., Tong, G. and Ballard, C. (2019) Treatment Combinations for Alz-heimer’s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer’s Disease, 67, 779-794.
https://doi.org/10.3233/JAD-180766
|
|
[3]
|
Rostagno, A.A. (2022) Pathogenesis of Alzheimer’s Disease. International Journal of Molecular Sciences, 24, Article 107.
https://doi.org/10.3390/ijms24010107
|
|
[4]
|
Ballard, C., Gauthier, S., Corbett, A., et al. (2011) Alzheimer’s Disease. The Lancet, 377, 1019-1031.
https://doi.org/10.1016/S0140-6736(10)61349-9
|
|
[5]
|
Hinault, C., Caroli-Bosc, P., Bost, F., et al. (2023) Critical Overview on Endocrine Disruptors in Diabetes Mellitus. International Journal of Molecular Sciences, 24, Article 4537.
https://doi.org/10.3390/ijms24054537
|
|
[6]
|
Laakso, M. (2019) Biomarkers for Type 2 Diabetes. Molecular Metabolism, 27, S139-S146.
https://doi.org/10.1016/j.molmet.2019.06.016
|
|
[7]
|
Shieh, J.C., Huang, P.T. and Lin, Y.F. (2020) Alzheimer’s Disease and Dia-betes: Insulin Signaling as the Bridge Linking Two Pathologies. Molecular Neurobiology, 57, 1966-1977.
https://doi.org/10.1007/s12035-019-01858-5
|
|
[8]
|
Takasugi, N., Komai, M., Kaneshiro, N., et al. (2023) The Pursuit of the “In-side” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease? Cells, 12, Article 454.
https://doi.org/10.3390/cells12030454
|
|
[9]
|
Orobets, K.S. and Karamyshev, A.L. (2023) Amyloid Precursor Protein and Alz-heimer’s Disease. International Journal of Molecular Sciences, 24, Article 14794.
https://doi.org/10.3390/ijms241914794
|
|
[10]
|
Tiwari, S., Atluri, V., Kaushik, A., et al. (2019) Alzheimer’s Disease: Pathogenesis, Diagnostics, and Therapeutics. International Journal of Nanomedicine, 14, 5541-5554.
https://doi.org/10.2147/IJN.S200490
|
|
[11]
|
Sreenivasachary, N., Kroth, H., Benderitter, P., et al. (2017) Discovery and Character-ization of Novel Indole and 7-Azaindole Derivatives as Inhibitors of Beta-Amyloid-42 Aggregation for the Treatment of Alzheimer’s Disease. Bioorganic & Medicinal Chemistry Letters, 27, 1405-1411.
https://doi.org/10.1016/j.bmcl.2017.02.001
|
|
[12]
|
Long, J.M. and Holtzman, D.M. (2019) Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 179, 312-339.
https://doi.org/10.1016/j.cell.2019.09.001
|
|
[13]
|
Masters, C.L. and Selkoe, D.J. (2012) Biochemistry of Amyloid Beta-Protein and Amyloid Deposits in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2, a006262.
https://doi.org/10.1101/cshperspect.a006262
|
|
[14]
|
Mucke, L. and Selkoe, D.J. (2012) Neurotoxicity of Amyloid Beta-Protein: Synaptic and Network Dysfunction. Cold Spring Harbor Perspectives in Medicine, 2, a006338.
https://doi.org/10.1101/cshperspect.a006338
|
|
[15]
|
Musiek, E.S. and Holtzman, D.M. (2015) Three Dimensions of the Amyloid Hypothesis: Time, Space and “Wingmen”. Nature Neuroscience, 18, 800-806.
https://doi.org/10.1038/nn.4018
|
|
[16]
|
Tarawneh, R., D’angelo, G., Macy, E., et al. (2011) Visinin-Like Protein-1: Diagnostic and Prognostic Biomarker in Alzheimer’s Disease. Annals of Neurology, 70, 274-285.
https://doi.org/10.1002/ana.22448
|
|
[17]
|
Ferrari, C. and Sorbi, S. (2021) The Complexity of Alzheimer’s Disease: An Evolving Puzzle. Physiological Reviews, 101, 1047-1081.
https://doi.org/10.1152/physrev.00015.2020
|
|
[18]
|
Maheshwari, S. (2023) AGEs RAGE Pathways: Alzheimer’s Disease. Drug Research (Stuttg), 73, 251-254.
https://doi.org/10.1055/a-2008-7948
|
|
[19]
|
Moloney, C.M., Lowe, V.J. and Murray, M.E. (2021) Visualization of Neurofibrillary Tangle Maturity in Alzheimer’s Disease: A Clinicopathologic Perspective for Biomarker Research. Alzheimer’s & Dementia, 17, 1554-1574.
https://doi.org/10.1002/alz.12321
|
|
[20]
|
Pîrşcoveanu, D., Pirici, I., Tudorică, V., et al. (2017) Tau Protein in Neurodegenerative Diseases—A Review. Romanian Journal of Morphology and Embryology, 58, 1141-1150.
|
|
[21]
|
Huang, H.C. and Jiang, Z.F. (2009) Accumulated Amyloid-Beta Peptide and Hyperphosphorylated Tau Protein: Relationship and Links in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 16, 15-27.
https://doi.org/10.3233/JAD-2009-0960
|
|
[22]
|
Šimić, G., Babić, L.M., Wray, S., et al. (2016) Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 6, Article 6.
https://doi.org/10.3390/biom6010006
|
|
[23]
|
Serrano-Pozo, A., Frosch, M.P., Masliah, E., et al. (2011) Neuropathological Altera-tions in Alzheimer’s Disease. Cold Spring Harbor Perspectives in Medicine, 1, a006189.
https://doi.org/10.1101/cshperspect.a006189
|
|
[24]
|
Khan, S., Barve, K.H. and Kumar, M.S. (2020) Recent Advancements in Path-ogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology, 18, 1106-1125.
https://doi.org/10.2174/1570159X18666200528142429
|
|
[25]
|
Huang, F., Wang, M., Liu, R., et al. (2019) CDT2-Controlled Cell Cycle Reentry Regulates the Pathogenesis of Alzheimer’s Disease. Alzheimer’s & Dementia, 15, 217-231.
https://doi.org/10.1016/j.jalz.2018.08.013
|
|
[26]
|
Han-Chang H, Zhao-Feng J. (2009) Accumulated Amyloid-β Peptide and Hyper-phosphorylated Tau Protein: Relationship and Links in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 16, 15-27.
https://doi.org/10.3233/JAD-2009-0960
|
|
[27]
|
Heneka, M.T., Carson, M.J., El, K.J., et al. (2015) Neuroinflammation in Alz-heimer’s Disease. The Lancet Neurology, 14, 388-405.
https://doi.org/10.1016/S1474-4422(15)70016-5
|
|
[28]
|
Lyman, M., Lloyd, D.G., Ji, X., et al. (2014) Neuroinflammation: The Role and Consequences. Neuroscience Research, 79, 1-12.
https://doi.org/10.1016/j.neures.2013.10.004
|
|
[29]
|
Kwon, H.S. and Koh, S.H. (2020) Neuroinflammation in Neurodegenerative Disorders: The Roles of Microglia and Astrocytes. Translational Neurodegeneration, 9, Article No. 42.
https://doi.org/10.1186/s40035-020-00221-2
|
|
[30]
|
Hampel, H., Caraci, F., Cuello, A.C., et al. (2020) A Path toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer’s Disease. Frontiers in Immunology, 11, Article 456.
https://doi.org/10.3389/fimmu.2020.00456
|
|
[31]
|
Ma, C., Hong, F. and Yang, S. (2022) Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27, Article 1210.
https://doi.org/10.3390/molecules27041210
|
|
[32]
|
Zhang, G., Wang, Z., Hu, H., et al. (2021) Microglia in Alzheimer’s Disease: A Target for Therapeutic Intervention. Frontiers in Cellular Neuroscience, 15, Article 749587.
https://doi.org/10.3389/fncel.2021.749587
|
|
[33]
|
Al-Ghraiybah, N.F., Wang, J., Alkhalifa, A.E., et al. (2022) Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease. International Journal of Molecular Sciences, 23, Article 10572.
https://doi.org/10.3390/ijms231810572
|
|
[34]
|
Wolf, S.A., Boddeke, H.W. and Kettenmann, H. (2017) Microglia in Physiology and Disease. Annual Review of Physiology, 79, 619-643.
https://doi.org/10.1146/annurev-physiol-022516-034406
|
|
[35]
|
He, X.F., Xu, J.H., Li, G., et al. (2020) NLRP3-Dependent Microglial Training Impaired the Clearance of Amyloid-Beta and Aggravated the Cogni-tive Decline in Alzheimer’s Disease. Cell Death & Disease, 11, Article No. 849.
https://doi.org/10.1038/s41419-020-03072-x
|
|
[36]
|
De Oliveira, P., Cella, C., Locker, N., et al. (2022) Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice. Journal of Neuroscience, 42, 3494-3509.
https://doi.org/10.1523/JNEUROSCI.2162-21.2022
|
|
[37]
|
Feng, Y.S., Tan, Z.X., Wu, L.Y., et al. (2020) The Involvement of NLRP3 Inflammasome in the Treatment of Alzheimer’s Disease. Ageing Re-search Reviews, 64, Article ID: 101192.
https://doi.org/10.1016/j.arr.2020.101192
|
|
[38]
|
Breijyeh, Z. and Karaman, R. (2020) Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, 25, Article 5789.
https://doi.org/10.3390/molecules25245789
|
|
[39]
|
(2023) 2023 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 19, 1598-1695.
https://doi.org/10.1002/alz.13016
|
|
[40]
|
Bird, T.D. (2008) Genetic Aspects of Alzheimer Disease. Genetics in Medicine, 10, 231-239.
https://doi.org/10.1097/GIM.0b013e31816b64dc
|
|
[41]
|
Sasaguri, H., Nilsson, P., Hashimoto, S., et al. (2017) APP Mouse Models for Alzheimer’s Disease Preclinical Studies. The EMBO Journal, 36, 2473-2487.
https://doi.org/10.15252/embj.201797397
|
|
[42]
|
Baranello, R.J., Bharani, K.L., Padmaraju, V., et al. (2015) Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and Their Role in Alzheimer’s Disease. Current Alzheimer Research, 12, 32-46.
https://doi.org/10.2174/1567205012666141218140953
|
|
[43]
|
Selkoe, D.J. and Hardy, J. (2016) The Amyloid Hypothesis of Alz-heimer’s Disease at 25 Years. EMBO Molecular Medicine, 8, 595-608.
https://doi.org/10.15252/emmm.201606210
|
|
[44]
|
Hardy, J. and Selkoe, D.J. (2002) The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356.
https://doi.org/10.1126/science.1072994
|
|
[45]
|
Farrer, L.A., Cupples, L.A., Haines, J.L., et al. (1997) Effects of Age, Sex, and Ethnicity on the Association between Apolipoprotein E Genotype and Alzheimer Disease. A Meta-Analysis. APOE and Alz-heimer Disease Meta Analysis Consortium. The Journal of the American Medical Association, 278, 1349-1356.
|
|
[46]
|
Kim, J., Basak, J.M. and Holtzman, D.M. (2009) The Role of Apolipoprotein E in Alzheimer’s Disease. Neuron, 63, 287-303.
https://doi.org/10.1016/j.neuron.2009.06.026
|
|
[47]
|
Jevtic, S., Sengar, A.S., Salter, M.W., et al. (2017) The Role of the Immune System in Alzheimer Disease: Etiology and Treatment. Ageing Research Reviews, 40, 84-94.
https://doi.org/10.1016/j.arr.2017.08.005
|
|
[48]
|
Weksler, M.E., Gouras, G., Relkin, N.R., et al. (2005) The Immune System, Am-yloid-Beta Peptide, and Alzheimer’s Disease. Immunological Reviews, 205, 244-256.
https://doi.org/10.1111/j.0105-2896.2005.00264.x
|
|
[49]
|
Wu, K.M., Zhang, Y.R., Huang, Y.Y., et al. (2021) The Role of the Im-mune System in Alzheimer’s Disease. Ageing Research Reviews, 70, Article ID: 101409.
https://doi.org/10.1016/j.arr.2021.101409
|
|
[50]
|
Holder, K. and Reddy, P.H. (2021) The COVID-19 Effect on the Immune System and Mitochondrial Dynamics in Diabetes, Obesity, and Dementia. Neuroscientist, 27, 331-339.
https://doi.org/10.1177/1073858420960443
|
|
[51]
|
de la Rubia, O.J., Sancho, C.S., Benlloch, M., et al. (2017) Impact of the Rela-tionship of Stress and the Immune System in the Appearance of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 55, 899-903.
https://doi.org/10.3233/JAD-160903
|
|
[52]
|
Maraschin, J.F. (2012) Classification of Diabetes. Advances in Experimental Medicine and Biology, 771, 12-19.
https://doi.org/10.1007/978-1-4614-5441-0_2
|
|
[53]
|
Sapra, A. and Bhandari, P. (2023) Diabetes. In: StatPearls, StatPearls Pub-lishing, Treasure Island, FL.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=31855345&query_hl=1
|
|
[54]
|
Li, L.M., Jiang, B.G. and Sun, L.L. (2022) HNF1A: From Monogenic Diabetes to Type 2 Diabetes and Gestational Diabetes Mellitus. Frontiers in Endocrinology (Lausanne), 13, Article 829565.
https://doi.org/10.3389/fendo.2022.829565
|
|
[55]
|
Pasarica, M., St, O.E. and Lee, E. (2021) Diabetes: Type 1 Diabetes. FP Essen-tials, 504, 11-15.
|
|
[56]
|
Forlenza, G.P., Moran, A. and Nathan, B. (2018) Other Specific Types of Diabetes. In: Cowie, C.C., et al., Eds., Diabetes in America, 3rd Edition, National Institute of Diabetes and Digestive and Kidney Diseases (US), Bethesda, MD, Chapter 6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=33651540&query_hl=1
|
|
[57]
|
Bonnefond, A., Unnikrishnan, R., Doria, A., et al. (2023) Monogenic Diabetes. Nature Reviews Disease Primers, 9, Article No. 12.
https://doi.org/10.1038/s41572-023-00421-w
|
|
[58]
|
Urbanova, J., Brunerova, L., Nunes, M.A., et al. (2020) MODY Diabetes and Screening of Gestational Diabetes. Ceska Gynekologie, 85, 124-130.
|
|
[59]
|
Lee, S.H., Park, S.Y. and Choi, C.S. (2022) Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes & Metabolism Journal, 46, 15-37.
https://doi.org/10.4093/dmj.2021.0280
|
|
[60]
|
Matulewicz, N. and Karczewska-Kupczewska, M. (2016) Insulin Resistance and Chronic Inflammation. Postępy Higieny i Medycyny Doświadczalnej (Online), 70, 1245-1258.
|
|
[61]
|
Shahwan, M., Alhumaydhi, F., Ashraf, G.M., et al. (2022) Role of Polyphenols in Combating Type 2 Diabetes and Insulin Resistance. International Journal of Bio-logical Macromolecules, 206, 567-579.
https://doi.org/10.1016/j.ijbiomac.2022.03.004
|
|
[62]
|
Ramadori, G., Ljubicic, S., Ricci, S., et al. (2019) S100A9 Extends Lifespan in Insulin Deficiency. Nature Communications, 10, Article No. 3545.
https://doi.org/10.1038/s41467-019-11498-x
|
|
[63]
|
Ruegsegger, G.N., Manjunatha, S., Summer, P., et al. (2019) Insulin Defi-ciency and Intranasal Insulin Alter Brain Mitochondrial Function: A Potential Factor for Dementia in Diabetes. FASEB Journal, 33, 4458-4472.
https://doi.org/10.1096/fj.201802043R
|
|
[64]
|
Van der Harg, J.M., Eggels, L., Bangel, F.N., et al. (2017) Insulin Deficiency Results in Reversible Protein Kinase A Activation and Tau Phosphorylation. Neurobiology of Disease, 103, 163-173.
https://doi.org/10.1016/j.nbd.2017.04.005
|
|
[65]
|
Cole, J.B. and Florez, J.C. (2020) Genetics of Diabetes Mellitus and Diabetes Complications. Nature Reviews Nephrology, 16, 377-390.
https://doi.org/10.1038/s41581-020-0278-5
|
|
[66]
|
Wei, J., Tian, J., Tang, C., et al. (2022) The Influence of Different Types of Diabetes on Vascular Complications. Journal of Diabetes Research, 2022, Article ID: 3448618.
https://doi.org/10.1155/2022/3448618
|
|
[67]
|
Singh, R., Chandel, S., Dey, D., et al. (2020) Epigenetic Modification and Therapeutic Targets of Diabetes Mellitus. Bioscience Reports, 40, BSR20202160.
https://doi.org/10.1042/BSR20202160
|
|
[68]
|
Tao, Z., Shi, A. and Zhao, J. (2015) Epidemiological Perspectives of Diabetes. Cell Biochemistry and Biophysics, 73, 181-185.
https://doi.org/10.1007/s12013-015-0598-4
|
|
[69]
|
Boles, A., Kandimalla, R. and Reddy, P.H. (2017) Dynamics of Diabetes and Obesity: Epidemiological Perspective. BBA Molecular Basis of Disease, 1863, 1026-1036.
https://doi.org/10.1016/j.bbadis.2017.01.016
|
|
[70]
|
Lotfy, M., Adeghate, J., Kalasz, H., et al. (2017) Chronic Complications of Diabetes Mellitus: A Mini Review. Current Diabetes Reviews, 13, 3-10.
https://doi.org/10.2174/1573399812666151016101622
|
|
[71]
|
Li, T., Cao, H.X. and Ke, D. (2021) Type 2 Diabetes Mellitus Easily Develops into Alzheimer’s Disease via Hyperglycemia and Insulin Resistance. Current Medical Science, 41, 1165-1171.
https://doi.org/10.1007/s11596-021-2467-2
|
|
[72]
|
Hernandez-Rodriguez, M., Clemente, C.F., Macias-Perez, M.E., et al. (2022) Contribution of Hyperglycemia-Induced Changes in Microglia to Alzheimer’s Disease Pathology. Pharmacological Reports, 74, 832-846.
https://doi.org/10.1007/s43440-022-00405-9
|
|
[73]
|
Lupaescu, A.V., Iavorschi, M. and Covasa, M. (2022) The Use of Bioactive Compounds in Hyperglycemia- and Amyloid Fibrils-Induced Toxicity in Type 2 Diabetes and Alzheimer’s Disease. Pharmaceutics, 14, Article 235.
https://doi.org/10.3390/pharmaceutics14020235
|
|
[74]
|
Ferreiro, E., Lanzillo, M., Canhoto, D., et al. (2020) Chronic Hyperglycemia Impairs Hippocampal Neurogenesis and Memory in an Alzheimer’s Disease Mouse Model. Neurobiology of Aging, 92, 98-113.
https://doi.org/10.1016/j.neurobiolaging.2020.04.003
|
|
[75]
|
Cacciatore, M., Grasso, E.A., Tripodi, R., et al. (2022) Impact of Glu-cose Metabolism on the Developing Brain. Frontiers in Endocrinology (Lausanne), 13, Article 1047545.
https://doi.org/10.3389/fendo.2022.1047545
|
|
[76]
|
Huo, Y., Grotle, A.K., Ybarbo, K.M., et al. (2020) Effects of Acute Hypergly-cemia on the Exercise Pressor Reflex in Healthy Rats. Autonomic Neuroscience, 229, Article ID: 102739.
https://doi.org/10.1016/j.autneu.2020.102739
|
|
[77]
|
Nunomura, A. and Perry, G. (2020) RNA and Oxidative Stress in Alzheimer’s Disease: Focus on microRNAs. Oxidative Medicine and Cellular Longevity, 2020, Article ID: 2638130.
https://doi.org/10.1155/2020/2638130
|
|
[78]
|
Newsholme, P., Cruzat, V.F., Keane, K.N., et al. (2016) Molecular Mechanisms of ROS Production and Oxidative Stress in Diabetes. Biochemical Journal, 473, 4527-4550.
https://doi.org/10.1042/BCJ20160503C
|
|
[79]
|
Poblete-Aro, C., Russell-Guzman, J., Parra, P., et al. (2018) Exercise and Oxidative Stress in Type 2 Diabetes Mellitus. Revista Médica de Chile, 146, 362-372.
https://doi.org/10.4067/s0034-98872018000300362
|
|
[80]
|
Calis, Z., Mogulkoc, R. and Baltaci, A.K. (2020) The Roles of Flavo-nols/Flavonoids in Neurodegeneration and Neuroinflammation. Mini-Reviews in Medicinal Chemistry, 20, 1475-1488.
https://doi.org/10.2174/1389557519666190617150051
|
|
[81]
|
Herradon, G., Ramos-Alvarez, M.P. and Gramage, E. (2019) Con-necting Metainflammation and Neuroinflammation Through the PTN-MK-RPTPbeta/zeta Axis: Relevance in Therapeutic Development. Frontiers in Pharmacology, 10, Article 377.
https://doi.org/10.3389/fphar.2019.00377
|
|
[82]
|
Kopp, K.O., Glotfelty, E.J., Li, Y., et al. (2022) Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research, 186, Article ID: 106550.
https://doi.org/10.1016/j.phrs.2022.106550
|
|
[83]
|
Choubaya, C., Chahine, N., Aoun, G., et al. (2021) Expression of Inflammatory Mediators in Periodontitis over Established Diabetes: An Experimental Study in Rats. Medical Archives, 75, 436-443.
https://doi.org/10.5455/medarh.2021.75.436-443
|
|
[84]
|
Heiston, E.M. and Malin, S.K. (2019) Impact of Exercise on Inflammatory Mediators of Metabolic and Vascular Insulin Resistance in Type 2 Diabetes. Advances in Experimental Medicine and Biology, 1134, 271-294.
https://doi.org/10.1007/978-3-030-12668-1_15
|
|
[85]
|
Kempuraj, D., Thangavel, R., Selvakumar, G.P., et al. (2017) Brain and Pe-ripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration. Frontiers in Cellular Neuroscience, 11, Article 216.
https://doi.org/10.3389/fncel.2017.00216
|
|
[86]
|
Azizi, G., Navabi, S.S., Al-Shukaili, A., et al. (2015) The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’s Disease. Sultan Qaboos University Medical Journal, 15, e305-e316.
https://doi.org/10.18295/squmj.2015.15.03.002
|
|
[87]
|
Deng, H.P. and Chai, J.K. (2009) The Effects and Mechanisms of Insulin on Systemic Inflammatory Response and Immune Cells in Severe Trauma, Burn Injury, and Sepsis. International Immunopharmacology, 9, 1251-1259.
https://doi.org/10.1016/j.intimp.2009.07.009
|
|
[88]
|
Ahluwalia, N. and Vellas, B. (2003) Immunologic and Inflammatory Mediators and Cognitive Decline in Alzheimer’s Disease. Immunology and Allergy Clinics of North America, 23, 103-115.
https://doi.org/10.1016/S0889-8561(02)00048-6
|
|
[89]
|
Sudar-Milovanovic, E., Gluvic, Z., Obradovic, M., et al. (2022) Trypto-phan Metabolism in Atherosclerosis and Diabetes. Current Medicinal Chemistry, 29, 99-113.
https://doi.org/10.2174/0929867328666210714153649
|
|
[90]
|
Pikula, A., Howard, B.V. and Seshadri, S. (2018) Stroke and Dia-betes. In: Cowie, C.C., et al., Eds., Diabetes in America, 3rd Edition, National Institute of Diabetes and Digestive and Kidney Diseases (US), Bethesda, MD, Chapter 19.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=33651535&query_hl=1
|
|
[91]
|
Elluru, R.G. (2013) Cutaneous Vascular Lesions. Facial Plastic Surgery Clinics of North America, 21, 111-126.
https://doi.org/10.1016/j.fsc.2012.11.001
|
|
[92]
|
Castillo, C., Saez-Orellana, F., Godoy, P.A., et al. (2022) Microglial Activation Modulated by P2X4R in Ischemia and Repercussions in Alzheimer’s Disease. Frontiers in Physiology, 13, Article 814999.
https://doi.org/10.3389/fphys.2022.814999
|
|
[93]
|
Ulamek-Koziol, M., Czuczwar, S.J., Januszewski, S., et al. (2020) Proteomic and Genomic Changes in Tau Protein, Which Are Associated with Alzheimer’s Disease after Ischemia-Reperfusion Brain Injury. In-ternational Journal of Molecular Sciences, 21, Article 892.
https://doi.org/10.3390/ijms21030892
|
|
[94]
|
Pakdin, M., Toutounchian, S., Namazi, S., et al. (2022) Type 2 Diabetes Mellitus and Alzheimer’s Disease: A Review of the Potential Links. Current Diabetes Reviews, 18, Article ID: e418409792.
https://doi.org/10.2174/1573399818666211105122545
|
|
[95]
|
Yin, F., Sancheti, H., Patil, I., et al. (2016) Energy Metabolism and Inflammation in Brain Aging and Alzheimer’s Disease. Free Radical Biology and Medicine, 100, 108-122.
https://doi.org/10.1016/j.freeradbiomed.2016.04.200
|
|
[96]
|
Sun, Y., Ma, C., Sun, H., et al. (2020) Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer’s Disease. Journal of Diabetes Research, 2020, Article ID: 4981814.
https://doi.org/10.1155/2020/4981814
|
|
[97]
|
Kubis-Kubiak, A., Dyba, A. and Piwowar, A. (2020) The Interplay between Diabetes and Alzheimer’s Disease—In the Hunt for Biomarkers. International Journal of Molecular Sciences, 21, Article 2744.
https://doi.org/10.3390/ijms21082744
|
|
[98]
|
Mahapatra, G., Gao, Z., Bateman, J.R., et al. (2023) Blood-Based Bioenergetic Pro-filing Reveals Differences in Mitochondrial Function Associated with Cognitive Performance and Alzheimer’s Disease. Alzheimer’s & Dementia, 19, 1466-1478.
https://doi.org/10.1002/alz.12731
|
|
[99]
|
Johnson, E., Dammer, E.B., Duong, D.M., et al. (2020) Large-Scale Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation. Nature Medicine, 26, 769-780.
https://doi.org/10.1038/s41591-020-0815-6
|